



**Tropical
Disease
Foundation Inc.**

2020-2021

Annual Report

INTRODUCTION

The current Covid pandemic started more than a year ago and was totally unexpected. It caught everyone by surprise, including the officers and staff of the Foundation. It meant that for the most part, management had to balance time and resources so that TDF could continue to deliver its primary mandate of research, service and training in relevant infectious diseases affecting our people. More importantly, the staff had to be protected from succumbing to this dreadful disease.

This Annual Report is a testament on how well the Foundation has achieved this mandate, primarily through the commitment of our staff, the generosity of our sponsors and partners, and the protection and guidance of Divine Providence. Our founder and pioneer in infectious disease, Dr. Thelma E. Tupasi, focused on research as a pillar in understanding the dynamics of infection, especially tuberculosis, on our people. She felt a tremendous

need to focus on these aspects of the infection so that we could improve the diagnosis, treatment and overall management of the disease. What will be reported in the next succeeding pages are the many clinical trials on Tuberculosis that are being carried out in partnership with several international institutions. These clinical trials use various drug combinations in an effort to shorten treatment of drug sensitive tuberculosis or manage multidrug resistant TB.

TDF not only functions as a clinical trial site but is the only laboratory in the Philippines that has been identified as a central reference laboratory to do TB diagnosis by the US National Institute of Allergy and Infectious Diseases. This unique distinction was alluded to by no less than Dr. Anthony Fauci in a speech in a convention in June. Our laboratory is periodically assessed and quality assured by the Patient Safety Monitoring in International Laboratories (SMILE) based in Bethesda, Maryland. With the advent of Covid, the laboratory staff underwent a series of training to achieve proficiency in PCR testing for the virus and is involved in several trials for Covid vaccines. An addition to our family is the Medical Research Unit headed by Dr. Rosario Capeding, a pediatric infectious disease expert. She is a pioneer and an established researcher in vaccines.

In terms of service, TDF continues to be part of the Public Private Mix DOTS Initiative of the Department of Health and a Satellite Treatment Center for MDRTB patients. It is also a referral laboratory for diagnosis of TB for NTRL of the DOH, and for health centers around the Makati area notably West Rembo, North Daang Hari and Masibay. We also partnered with a Korean Company, Radisen Technology, to set up an X-ray machine with an Artificial Intelligence which can give results in 5 seconds. The availability of this machine in the premises of the Foundation rightfully makes our site an expedient One Stop Shop for TB Diagnosis and Management.

Our training mandate has been limited because of the pandemic, and we can cite a few of these among which are the Community Engagement Webinars which have been funded by the Global TB Alliance. These webinars highlight the challenges and experience of our patients with tuberculosis. Thus far, we have had 6 webinars. Our staff members have undergone several sessions such as continuous training for maintenance and proficiency in different diagnostic processes, occupational safety, cybersecurity, primer on the provisions of the privacy law and such other relevant programs needed to run the Foundation smoothly and proficiently.

It is our fervent hope that we continue to perform our mandate of research, service and training on infectious diseases in the next succeeding years. Our founder, Dr. Thelma E. Tupasi who has blazed the trail, continues to inspire us even in the face of adversity.



ROBERTA C. ROMERO, MD
PRESIDENT

ABOUT TDF

The Tropical Disease Foundation, Inc. is a private, non-stock, non-profit, nongovernment organization founded in 1984 by a group of physicians in the Research Institute for Tropical Medicine. The founding chairman was Dr. Jesus Azurin, then Secretary of Health. The TDF began a legacy of quality research, service and training in infectious diseases.

OUR VISION AND MISSION

The Tropical Disease Foundation, Inc. believes in equitable, universal access to health for economic prosperity. Its programs and projects encourage participation in the national and local communities through its research, training, health care service provision and advocacies.

OUR THRUSTS

1. To conduct research, training and service in infectious diseases of public health importance
2. To enter into partnership with public and private agencies in the implementation of programs in the control of infectious diseases
3. To ensure technology transfer in developing human resources for health nationally and internationally through collaboration with national and international institutions
4. To serve as a national and international training center for infectious diseases



Researches

1. TRUNCATE -TB

- *Protocol Title:* “Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis”
- *Sponsor:* University College London (UCL)/ National University Hospital (NUH) Singapore
- *Trial Duration:* Approximately 5 years
- *Principal Investigator:* Dr. Rholine Gem Martin Veto

Objectives:

- The primary aim is to test the hypothesis that the TRUNCATE-TB management strategy is non-inferior to the standard TB management strategy assessed by the proportion of patients with unsatisfactory outcome at 2 years after randomisation.
- The secondary aim is to assess the possible advantages of the TRUNCATE-TB management strategy compared to the standard management strategy from the patient perspective, the programme perspective and to assess cost-effectiveness.

Study Updates:

Ethics Committee Initial Approval:	19 Jan 2017
Coordinator’s meeting:	09 Feb 2018
Site Initiation visit:	12 Feb 2018
First subject enrolled:	13 Apr 2018
End of recruitment:	18 Mar 2020
Total patients screened:	66
Total patients randomized:	42
Projected last patient visit:	Dec 2021

Tests Conducted:

Total Number of Samples	801
AFB Smear Microscopy	757
TB Culture	800
DST	26
GeneXpert MTB/Rif	77

2. SIMPLICITB

- *Protocol Title:* “An Open-Label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4-month Treatment of Bedaquiline plus Pretomanid plus Moxifloxacin plus Pyrazinamide (BPamZ) Compared to a 6-month Treatment of HRZE/HR (Control) in Adult Participants with Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPamZ in Adult Participants with Drug Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB).”
- *Study Protocol No.:* NC-008 (B-Pa-M-Z)
- *Protocol Name:* SimpliciTB
- *Sponsor:* Global Alliance for TB Drug Development
- *Trial Duration:* Approximately 4 years
- *Principal Investigator:* Dr. Janice Caoili

Study Updates:

Ethics Committee Initial Approval:	21 May 2018
Site Initiation Visit:	23 January 2019
First patient enrolled:	04 Mar 2019
Total patients enrolled to date:	18
Total patients randomized:	9
Projected last patient visit:	28 Feb 2022

Tests Conducted:

Total Number of Samples	114
TB Culture	114
GeneXpert MTB/Rif	1

3. ROSETTA

- *Protocol Title:* “Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct”
- *Protocol Name:* ROSETTA
- *Sponsor:* National University Hospital (NUH) Singapore through the National Medical Research Council, Singapore
- *Trial Duration:* 1 year
- *Principal Investigator:* Dr. Rholine Gem Martin Veto

Study Updates:

Ethics Committee Initial Presentation: 16 June 2020
IRB Approval with revisions: 07 Oct 2020
(for re-request of approval due to PFDA recommendations)
Patients enrolled:2
Patients randomized: 1
Last patient visit:Jun 2021

Tests Conducted:

TB Culture	262
Total Number of Samples ... 264	DST..... 18
AFB Smear Microscopy	44
	HAIN MTBDRplus.....3

4. PATERNITY SURVEY

- *Protocol Title:* A Survey Assessing Male Reproduction During or After Treatment Containing Pretomanid
- *Survey Protocol Name:* PATERNITY SURVEY
- *Sponsor:* Global TB Alliance
- *Principal Investigator:* Dr. Janice Caoili

- *Objective:* To evaluate the paternity status in male participants who have received a pretomanid containing regimen in one of the following TB Alliance clinical trials: STAND, Nix-TB, SimpliciTB or ZeNix.

Study Milestones:

Site Initiation Visit: 09 Dec 2020
Total patients eligible: 10
Total patients completed the survey:9

5. INACTIVATED COVID-19 VACCINE (VERO CELLS)

- *Protocol Title:* A Multi-National, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated for the Prevention of COVID-19 in Healthy Adults Aged 18 Years and Older
- *Sponsor:* Shenzhen Kangtai Biological Products Co., Ltd. and Beijing Minhai Biotechnology Co., Ltd
- *Principal Investigator:* Dr. Gelza Mae Zabat

Study Milestone:

Site Selection Visit:April 21, 2021
Initial Submission to Ethics: May 17, 2021
Initial Approval of Ethics:June 30,2021





6. ARCoV-005

A Global, Multi-center, Randomized, Double-Blind, Placebocontrolled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine in Population Aged 18 Years and Older

Principal Investigator:
Dr. Rod T. Castro

Study Milestone:
Initial Submission to
Ethics Review:
July 09, 2021



MEDICAL RESEARCH UNIT (MRU) *Researches*

The TDF expanded its research services through Medical-Research Unit (MRU). The MRU is founded last October 2019 and headed by one of the country's top clinical researcher, Dr. Maria Rosario Zeta Capeding. Dr. Rose is a pediatrician specializing in infectious disease. A memorial awardee of Dr. Jose P. Rizal in research and a Scientist II of the Department of Science and Technology. She has worked as lead investigator in various clinical trials. Currently, TDF-MRU is engaged in seven projects which focus on vaccines:

Clinical Trials under Dr. Rose Capeding as Principal Investigator

7. A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells), for the prevention of COVID-19 in adults aged 18 years and older.

- *Clinical Trial Site:* Alaminos Clinical Trial Site
52D Fandino St., Brgy 3 Alaminos, Laguna, 4001, Philippines

- *Sponsor:* WestVac Biopharma Co., LTD.and West China Hospital of Sichuan University

Study Milestone:

Completed enrollment of 3054 study participants
Completed vaccination phase, follow-up activities ongoing

8. A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

- *Clinical Trial Site:* San Francisco Multipurpose Bldg.
Brgy. San Francisco, San Pablo City, Laguna 4000 Philippines
- *Sponsor:* Janssen Vaccines & Prevention B.V.

Study Milestone:

Completed enrollment of 281 study participants
Completed vaccination phase, booster vaccination ongoing

9. A Multi-national, Multi-center, Randomized, Double-Blind, Active Controlled, Phase III Study to Investigate the Efficacy and Safety of 'GC3107 (BCG Vaccine)' after Intradermal Administration in Healthy Infants

- *Clinical Trial Site:* TDF-MRU Site
Room 2002 Medical Plaza Building, Amorsolo Street corner Dela Rosa, Makati City

- *Sponsor:* Green Cross Corporation

Study Milestone:

Completed enrollment of 150 study participants
Completed vaccination phase, follow-up activities ongoing

10. Long Term Follow-up of Immunogenicity of Healthy Filipino Adults and Children who participated in Phase I study

- *Clinical Trial Site:* TDF-MRU
Room 2002 Medical Plaza Building, Amorsolo St.
corner Dela Rosa, Makati City
- *Sponsor:*
International Vaccine Institute, KOREA

Study Milestone:

Enrolled 136 study participants,
3 years study completed



Clinical Trials under Dr. Edison Alberto as Principal Investigator

11. A multi-national, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy, safety and immunogenicity of SARS-CoV-2 Vaccine (VeroCells), Inactivated for the prevention of COVID-19 in healthy adults aged 18 years and older

- *Clinical Trial Site:* HEALTH INDEX MULTISPECIALTY CLINIC-CLINICAL RESEARCH CENTER
Toclong 2B Road, Brgy. Toclong 2B, Imus Cavite
- *Sponsor:* Shenzhen Kangtai Biological Products Co., Ltd.
and Beijing Minhai Biotechnology Co., Ltd

Study Milestone:

Total Screened:	3, 351
Total Enrolled:	2,800
Total Immunogenicity:	581
Total Non-Immunogenicity:	2219



Subjects personally reading the ICF prior to study overview by research staff



Research staff conducting study overview prior to one-on-one informed consent process



Diary card where subjects will record their vaccine reactions instructions session

12. Impact of Vaccination using the Clover SCB-2019 COVID-19 vaccine on Household Transmission of SARS-CoV-2 Infection (HHT)

- *Clinical Trial Site:* HEALTH INDEX MULTISPECIALTY CLINIC Bacoor, Cavite
- *Sponsor:* International Vaccine Institute

Study Milestone:

Enrollment and COVID Surveillance Finished, ongoing Data analysis.

13. A Double-Blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of AS03-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) for the Prevention of SARS-CoV-2-mediated COVID-19 in Participants Aged 18 years and Older

- *Clinical Trial Site:* Health Index Multispecialty Clinic Barangay Mambog 1, Bacoor, Cavite
- *Sponsor:* Clover Biopharmaceuticals Pte Ltd

Ongoing implementation of amendment of the above study which includes booster to the subjects enrolled and addition of around 1000 adolescent subjects in the Philippines.



Services

1. TDF TB-DOTS CLINIC (PUBLIC-PRIVATE MIX DOTS INITIATIVE)



Tropical Disease Foundation, Inc. (TDF) offers a public-private mixed Directly Observed Treatment, Short-course (DOTS) clinic for patients who have symptoms suggestive of tuberculosis (TB) or who are suspected to have TB by healthcare providers. DOTS is the most effective means of controlling the spread of tuberculosis and by involving the public and the private sector, case finding and engagement to treatment is intensified.

TDF TB-DOTS Clinic caters to patients who live or work within the catchment area whether they are walk-in patients or referrals by physicians of nearby hospitals such as Makati Medical Center, diagnostic clinics, schools, business establishments and offices.

For patients found to have a positive sputum test (usually GeneXpert), treatment is discussed, and options are presented to patients where they may avail of treatment. TDF-DOTS Clinic envisions achievement of the millennium development goal by serving more TB patients in the future. In the time of community quarantine, the clinic has arranged skeletal staffing and work from home arrangements to ensure continuation of care, and safety of clinic staff.

- *Sponsoring Organization:*
TB kits (drugs) and laboratory supplies are provided by National TB Program through the Makati City Health Department.

- *Accomplishments:*
of Patient Screened: 104
of Patient Enrolled: 19
of Patient Completed treatment:
- Cured: 8
- Treatment Completed: 6
- Ongoing Treatment: 5

2. SATELLITE TREATMENT CENTER FOR MDR-TB

The performance of the Satellite Treatment Center (STC) for Multidrug-Resistant TB (MDRT-TB) in the past year is as follows:

- Number of All Presumptive DR-TB Screened: 137
- Number of All Presumptive DR-TB Tested: 137
- Number of All Confirmed Rifampicin Resistant TB: 31
- Number of cases registered: 20
- o Bacteriologically-confirmed RR/MDR-TB: 11
- o Clinically-diagnosed MDR-TB: 6
- o Other Drug-resistant TB case: 3

As of JULY 31, 2021, the clinic census is at 21 patients, including patients supervised by Community Treatment Partners. The STC currently has one (1) Philippine Business for Social Progress (PBSP)-seconded nurse on board. Patients are followed-up regularly through phone calls and/or internet messaging platforms in between monthly clinic visits.

3. RAPID TB DIAGNOSTIC LABORATORY (RTDL) OF THE PMDT PROGRAM

TDF laboratory is also a Rapid TB Diagnostic Laboratory (RTDL) of the Programmatic Management of Drug-Resistant TB patients. As an RTDL, TDF performs GeneXpert MTB/RIF assay for the patients of the program and participates in the bi-annual data quality check activity of PMDT. From August 1, 2020 to July 31, 2021, a total of 405 tests were conducted for patients of the PMDT. There was a 50% decline in the number of tests conducted, which may be attributed to the pandemic.

4. CULTURE LABORATORY OF THE PMDT PROGRAM

As a part of the TB Culture Laboratory Network of the NTP, TDF renders its services to the following satellite treatment centers (STCs): North Daang Hari STC, Elias Aldana STC, TDF STC, West Rembo STC, BJMP MMDJ6 STC, and Masambong STC. For the fiscal year 2020-2021, a total of 1560 samples were received and processed.

5. PHOENIX MDR-TB (PROTECTING HOUSEHOLDS ON EXPOSURE TO NEWLY DIAGNOSED INDEX MULTI- DRUG-RESISTANT TUBERCULOSIS PATIENTS)

A Phase III, open-label, randomized clinical trial to compare the efficacy and safety of delamanid versus 26 weeks of isoniazid for preventing confirmed or probable active TB during 96 weeks of follow-up among high-risk household contacts of adults with multidrug-resistant TB.

- *Sponsor:* National Institute of Allergy and Infectious Diseases
- *Laboratory Role:* Contracted Mycobacteriology Laboratory
- *Duration:* 2019 – 2025

Tests Conducted:

Total Number of Samples	423
AFB Smear Microscopy	185
TB Culture	196
GeneXpert Ultra	115
HAIN MTBDRplus	67
QFT TB Gold Plus	146



6. TMC207-C211

A phase 2, open-label, multicenter, single-arm study to evaluate the pharmacokinetics, safety, tolerability and anti-mycobacterial activity of TMC207 in combination with a background regimen of multidrug resistant TB (MDR-TB) medications for the treatment of children and adolescents 0 months to <18 years of age who have confirmed or probably pulmonary MDR-TB.

- *Sponsor:* Janssen Research and Development
- *Laboratory Role:*
Country Central Mycobacteriology Laboratory
- *Duration:* 2016 – 2025

Tests Conducted:

Total Number of Samples	55
AFB Smear Microscopy	50
GeneXpert MTB/RIF	9
TB Culture	50
HAIN CM	5



7. BPAL OPERATIONAL RESEARCH (LIFT-TB PROJECT)

TDF Laboratory was contracted by PBSP to perform HAIN MTBDRsl for the BPAL Operational Research until the reagents of NTRL arrives. The Letter of Agreement took effect on May 24, 2021 and was terminated on August 20, 2021 as the laboratory has consumed all reagents allotted for the project. A total of 146 samples from 27 sites were processed by TDF Laboratory in its 3-month involvement.



Partnerships

1. COMMUNITY ENGAGEMENT PROJECT (GLOBAL TB ALLIANCE)


With community quarantine still in place, the project shifted its activities to online webinars highlighting the challenges and experiences brought about by TB through the perspectives of public partners and patients. Six webinar sessions have been produced together with TB People PH. Updates are provided to TB Alliance through online questionnaires prepared by the sponsor. TB Alliance has also conducted Community Engagement (CE) Forums where CE sites share experiences in implementation.

- CE Forum 1:..... 16 September 2020
- CE Forum 2..... 30 September 2020
- CE Forum 3..... 13 July 2021

TB Webinar Series:

- i. TB and Impact of COVID-1926 February 2021
- ii. TB Champs..... 26 March 2021
- iii. TB and Disability.....29 April 2021
- iv. Gamutan Noon at Ngayon 31 May 2021
- v. TB and Family..... 02 July 2021

The project started in Oct 2019 and has been provided a no-cost extension until Dec 2021.





Tropical Disease Foundation was live.
Published by Envy Iason
February 25, 2021

TB 101 and COVID-19

Impact of COVID-19 to TB Management

15 Reactions 3 Comments 912 Views

2.7K People reached 80 Reactions, comments, and shares

912 3-Second Video Views Retention curve

View more video details

Like Comment Share

Comments Hide

Most relevant



Tropical Disease Foundation was live.
Published by Envy Iason
March 26, 2021

TB CHAMPS

46 Reactions 23 Comments 833 Views

2.5K People reached 132 Reactions, comments, and shares

833 3-Second Video Views Retention curve

View more video details

Love Comment Share

Comments Hide

Most relevant

Comment as Tropical Disc...



Tropical Disease Foundation was live.
Published by ZOCAM Video Livestream-Prod
April 25, 2021

Community Engagement: TB and Disability

We will be discussing TB and Disability

25 Reactions 3 Comments 1.1K Views

3K People reached 123 Reactions, comments, and shares

1.2K 3-Second Video Views Retention curve

View more video details

Like Comment Share

Comments Hide


Comment as Tropical Disc...

2. LEVERAGING INNOVATIONS FOR FASTER TREATMENT OF TUBERCULOSIS (LIFT-TB) PROJECT

In November 2020, TDF and the International Research Center (ITRC) of Korea entered into a collaboration to support the project entitled “Introduction of highly new effective treatment regimens for TB” for targeted work in the Philippines or LIFT-TB. The Leveraging Innovations for Faster Treatment of Tuberculosis (LIFT-TB) Project is a global initiative of TB Alliance (TBA) in collaboration with the ITRC and the KNCV Tuberculosis Foundation and the TDF as the local coordinating organization. It is funded by Korea International Cooperation Agency (KOICA) through the Global Disease Eradication Fund (GDEF).



The project supports the conduct of an operational research (OR) on the WHO-recommended novel short-all oral BPaL (Bedaquiline, Pretomanid and Linezolid) regimen for the treatment of multidrug resistant TB in the Philippines in collaboration with the National TB Control Program (NTP), Jose B. Lingad Memorial General Hospital (JBL), Lung Center of the Philippines (LCP), National TB Reference Laboratory (NTRL), Philippine Business for Social Progress (PBSP) and TDF. The project is expected to run from October 2020 to December 2022.



KEY ACTIVITIES AND ACHIEVEMENTS

COMPONENT	ACTIVITIES	ACCOMPLISHMENTS
Coordination with partners	Regular meetings for technical and administrative support	<ul style="list-style-type: none"> • Official launch in December 2020 attended by 184 stakeholders • The project has coordinated and participated in 51 meetings with local and international counterparts (Research Team, NTP, NTRL, PBSP, OR sites, ITRC) since October 2020.
Needs assessment	Provision of technical and administrative support for evaluation of baseline situation	<ul style="list-style-type: none"> • Needs assessment of 12 OR sites from January – March 2021 with Research Team and partners • Needs assessment of 18 laboratories from March – May 2021 with NTRL and partners
Implementation Plan		<ul style="list-style-type: none"> • The project developed and disseminated an implementation plan (May 2021) to supplement the protocol.
Training	Capacity building of stakeholders	<ul style="list-style-type: none"> • Training of Trainers (TOT) conducted on 19 – 21 May 2021 and attended by 85 participants • Training of National and Regional TB Medical Advisory Committee (TBMAC) members on 3-4 June 2021 and participated by 150 participants

KEY ACTIVITIES AND ACHIEVEMENTS

COMPONENT	ACTIVITIES	ACCOMPLISHMENTS
Training	Capacity building of stakeholders	<ul style="list-style-type: none"> • Orientation of NTP coordinators from Center for Health Development (CHD) offices on 26 May 2021 with 103 participants
Enrollment		<ul style="list-style-type: none"> • First patient was enrolled on 31 May 2021 from Jose B. Lingad Memorial General Hospital (OR site). • As of July 2021, the OR has enrolled 7 patients from 3 OR sites. • The project developed and disseminated a flyer indicating eligibility and non-eligibility criteria for the guidance of OR sites.
Laboratory Support		<ul style="list-style-type: none"> • The project provided coordination support for Laboratory capacity building on LPA and DST for medical technologists conducted by ITRC on 17 May 2021 and attended by 19 lab staff from NTRL and OR laboratories. • TDF TB Laboratory provided support for LPA testing to cover for shortage of LPA kits in NTRL.
Webpage	Publication of news articles	<ul style="list-style-type: none"> • As of this writing, the project has published 11 articles to provide technical guidance to implementers.

3. TDF-RADISEN X-RAY FACILITY

TDF and Radisen Technology Pte Ltd. of Singapore, a venture company that developed AI tuberculosis reading solutions (AXIR-CX) and X-ray devices, joined hands to launch a One Stop Community Tuberculosis (TB) Service and a joint research of TB Screening enhancement topics. According to Dr. Romero, TDF President, “Quick and quick detection, treatment, and coping with tuberculosis are the most important thing.” We will do our best to combat tuberculosis in all parts of the Philippines using Radisen’s AI solution AXIR-CX.”

• *Milestone:*

Project with Radisen using new digital chest x-ray technology with artificial intelligence.

Preliminary discussions with Radisen were made	March 2021
Agreement Signed:	May 2021
Preparatory Work for facility started:	June 2021 (Engaging Suppliers, License and Permit Application, Staff Hiring)
Renovation for Xray facility completed:	August 2021
Patients to Date:	3

4. WELLCOME PROJECT

On May 18, 2021, The Chancellor, Masters, Scholars of the University of Oxford and the TDF signed a collaborative agreement for the project entitled “Enabling ISARIC Clinical Characterisation Protocol (CCP) roll out in LMICs”, awarded by Wellcome Trust, funder of the project.

TDF is the regional and local coordinator in inviting health care providers to contribute to the global COVID-19 database. It is headed by Dra. Janice Campos Caoili, Regional Team Lead. The project duration is from June 2021 up to November of 2022.


X-PRAY



5. COVID-19 MOLECULAR LABORATORY

The partnership between TDF, Ayala Healthcare Holdings, Inc., HMC, and Bloomberry Cultural Foundation, Inc. (BCFI) continued until March 2021. From April 2021 to the present, the partnership has been maintained between TDF and BCFI.

The Tropical Disease Foundation, Inc. COVID-19 RT-PCR laboratory is a duly licensed RT-PCR Laboratory for the detection of SARS-CoV-2. As part of the COVID-19 Laboratory Network, it has tested over 70,000 samples since its establishment in June 2020.



6. IN VITRO ANTITUBERCULAR POTENTIAL OF ESSENTIAL OILS FROM PHILIPPINE PLANTS

In partnership with the University of Santo Tomas, the TB Laboratory of TDF conducted in vitro testing of 26 essential oils against *M. tuberculosis*. Essential oils were extracted by the investigators from the University of Santo Tomas and were sent to TDF Laboratory for testing against resistant and susceptible strains of TB. Dr. Alicia Aguinaldo of the University of Santo Tomas is the proponent of the project that was funded by PITAHC.


7. PHILIPPINE PRIVATE SECTOR DIAGNOSTICS CONSORTIUM (PPSDC) GENERAL ASSEMBLY

TDF is a member of the Philippine Private Sector Diagnostics Consortium (PPSDC) and is represented by its Laboratory Manager, Anthony Geronimo. The General Assembly of the PPSDC was held on November 18, 2020. Due to the community quarantine, the event was held online via Zoom. In this meeting, Anthony Geronimo was sworn in as a member of the Governing Council of the PPSDC.

8. CEREMONIAL MEMORANDUM OF UNDERTAKING (MOU)

SIGNING BETWEEN DEPARTMENT OF HEALTH (DOH), PHILIPPINE COALITION AGAINST TUBERCULOSIS (PHILCAT), AND PPSDC (JULY 8, 2021)

TDF remains to be an active member of the PhilCAT and is also a member of the PPSDC. On July 8, 2021, through an online meeting, a MOU was ceremonially signed by the DOH, PhilCAT, and the PPSDC. TDF was represented by its Laboratory Manager, Mr. Anthony Geronimo. By signing the MOU, Consortium members were formally introduced to different regional Center for Health Development and were welcomed as part of the TB Laboratory Network.



LABORATORY *Activities*

DATA QUALITY CHECK FOR GENEXPERT MTB/RIF JULY 15, 2021

A one day data quality check for GeneXpert MTB/RIF was attended by Phoebe Hannah Bauzon of TDF laboratory. The goal of the activity was to verify the data of each Rapid TB Diagnostic Laboratory under the PMDT. In the said activity, data input from PMDT RTDL were validated.

EQA PERFORMANCE OF TDF TB LABORATORY FOR FY 2020-2021

Mycobacteriology	--2020-- Round 2	--2021-- Round 1
AFB Microscopy	80%	75%
MTB Identification	100%	100%
MTB Susceptibility, first line	100%	100%
MTB Susceptibility, second line	100%	100%

Mycobacteriology, Molecular	----- 2020 ----- Round 3 Round 4	----- 2021 ----- Round 1 Round 2
GeneXpert MTB-RIF Ultra	100% 100%	100% 100%
HAIN MTBDRplus*	100% 100%	100% 100%
HAIN MTBDRsl*	100% 100%	100% 89%

*Granted "Area of Excellence" Status

IGRA

	----- 2020 ----- Round 4 Round 5 Round 6	----- 2021 ----- Round 1 Round 2 Round 3
QuantIFERON TB Gold Plus	100% 50% 100%	100% 100% 100%



Trainings

EXTRAMURAL

MAKATI MEDICAL CENTER FELLOWSHIP ROTATION PROGRAM

Training program with MMC Infectious Diseases and Pulmonology Departments for fellows to be familiarized with clinical and laboratory TB management. The program started Sep 2014, and TDF has accommodated 4 fellows for the current year.

INTRAMURAL

EMPLOYEE NAME	TITLE OF TRAINING	DATE
Leilani Naval	Digital Learning Tools	September 22, 2020
Leilani Naval	Facilitating Positive Digital Learning	October 13-14, 2020
Leilani Naval	Conversation on the New Normal -- Work Guidelines	November 6, 2020
Anthony A. Geronimo	Philippine Private Sector Diagnostics Consortium	November 18, 2020
Leilani Naval	Improving your NGO's Remote Practices	November 27, 2020
Leilani Naval	The Colliding Epidemics of TB and Covid	January 27, 2021

EMPLOYEE NAME	TITLE OF TRAINING	DATE
Marita I. Nucum	Labor Laws for NGO Workers	Feb. 19, 2021
Christine Larryse Evangelista Mark Joseph I. Palec	RT-PCR Training for the Detection of SARS-CoV-2	Feb. 22-24, 2021
Leilani Naval	The Data Privacy Act, CSOs and Financial Services	February 26, 2021
Leilani Naval	Orientation: Capacity Assessment Tool	March 30, 2021
Marita I. Nucum John Phillip C. Ubalde	Occupational Safety and Health for HR Personnel	April 23, 2021
Christine Larryse Evangelista Mark Joseph I. Palec Marilou Salvana Phobe Hannah Bauzon	Online Training for GeneXpert Processing	May 14, 20 & 27, 2021
John Phillip C. Ubalde Manny C. Directo	Basic Occupational Safety and Health for Safety Officer I	May 19, 2021

EMPLOYEE NAME	TITLE OF TRAINING	DATE
Angelito M. Catindig Ma. Lourdes O. Cabanatan Maria Teresa A. Caridad	5th GMM and Webinar the effects of COVID-19 on the presentation of Financial Statement and Notes	May 19, 2021
Evelyn S. Joson	Virtual Privacy Awareness Week: Valuing Privacy in the Time of Digital Transformation	May 28, 2021
Rupert Rey J. Flores	Basic Occupational Safety and Health	June 16, 2021
Ricardo T. Taylo Jr	Innovate your Supplier Risk Management through Digital Transformation	June 24, 20221
Mhon Adrian G. Perena	SOPHOS: Business-Grade Cybersecurity Presentation	July 16, 2021
Angelito M. Catindig Ma. Lourdes O. Cabanatan Maria Teresa A. Caridad	Portfolio Management and Customer Onboarding Webinar	August 19, 2021

FINANCIAL SUMMARY

TROPICAL DISEASE FOUNDATION, INC.
(A Non-stock, Non-profit Organization)
STATEMENTS OF ASSETS, LIABILITIES AND FUND BALANCES

	Note	July 31	
		2021	2020
ASSETS			
Current Assets			
Cash and cash equivalents	4	P31,511,886	P18,842,676
Receivables	5	12,141,368	15,007,935
Investments in trust fund	6	68,966,888	74,425,443
Other current assets		365,366	596,424
Total Current Assets		112,985,508	108,872,478
Noncurrent Assets			
Investment property	7	4,086,807	5,087,872
Property and equipment	8	63,594,343	63,174,485
Other noncurrent assets	9	731,625	454,989
Total Noncurrent Assets		68,412,775	68,717,346
		P181,398,283	P177,589,824
LIABILITIES AND FUND BALANCES			
Current Liabilities			
Accrued expenses and other payables	10	P7,315,397	P9,361,422
Income tax payable		309,235	-
		7,624,632	9,361,422
Noncurrent Liability			
Net retirement benefit liability	17	8,225,082	13,641,667
Total Liabilities		15,849,714	23,003,089
Fund Balances			
General fund		97,822,521	86,278,676
Capital fund		35,308,150	35,889,357
Restricted fund	12	32,373,000	32,373,000
Other comprehensive income		44,838	45,702
Total Fund Balances		165,548,509	154,586,735
		P181,398,283	P177,589,824

See accompanying Notes to Financial Statements.

TROPICAL DISEASE FOUNDATION, INC.
(A Non-stock, Non-profit Organization)
STATEMENTS OF REVENUES AND EXPENSES

	Note	Years Ended July 31	
		2021	2020
REVENUES			
Sources of funds	13	P79,938,946	P39,482,437
Rental income	19	2,583,000	2,583,000
		82,521,946	42,065,437
PROGRAM EXPENSES			
	14	(68,914,863)	(44,095,690)
GENERAL AND ADMINISTRATIVE EXPENSES			
	15	(7,894,738)	(8,541,904)
OTHER INCOME - Net			
	16	5,807,825	2,096,405
EXCESS OF REVENUES OVER EXPENSES (EXPENSES OVER REVENUES) BEFORE INCOME TAX		11,520,170	(8,475,752)
INCOME TAX EXPENSE		18	557,532
		10,962,638	(8,585,283)
NET INCOME (LOSS)			
OTHER COMPREHENSIVE LOSS			
<i>Item to be reclassified to profit or loss when realized</i>			
Unrealized loss on fair value changes of investments	9	(864)	(23,760)
TOTAL COMPREHENSIVE INCOME (LOSS)		P10,961,774	(P8,609,043)

See accompanying Notes to Financial Statements.

TROPICAL DISEASE FOUNDATION, INC.
(A Non-stock, Non-profit Organization)

STATEMENTS OF CHANGES IN FUND BALANCES

	Note	Years Ended July 31	
		2021	2020
GENERAL FUND BALANCE			
Balance at beginning of year		P86,278,676	P91,364,347
Excess of revenues over expenses (expenses over revenues)		10,962,638	(8,585,283)
Transfer from capital fund	8	8,407,591	7,413,628
Transfer to capital fund	8	(7,826,384)	(3,914,016)
Balance at the end of year		97,822,521	86,278,676
CAPITAL FUND BALANCE			
Balance at beginning of year		35,889,357	39,388,969
Transfer to general fund	8	(8,407,591)	(7,413,628)
Additions to property and equipment	8	7,826,384	3,914,016
Balance at the end of year		35,308,150	35,889,357
RESTRICTED FUND BALANCE			
	12	32,373,000	32,373,000
OTHER COMPREHENSIVE INCOME			
<i>Reserve for Fair Value Changes of Investments</i>	9		
Balance at beginning of year		45,702	69,462
Unrealized loss on fair value changes		(864)	(23,760)
Balance at the end of year		44,838	45,702
		P165,548,509	P154,586,735

See accompanying Notes to Financial Statements.

TROPICAL DISEASE FOUNDATION, INC.
(A Non-stock, Non-profit Organization)

STATEMENTS OF CASH FLOWS

	Notes	Years Ended July 31	
		2021	2020
CASH FLOWS FROM OPERATING ACTIVITIES			
Excess of revenues over expenses (expenses over revenues) before income tax		P11,520,170	(P8,475,752)
Adjustments for:			
Depreciation and amortization	8	8,407,591	7,413,628
Investment income	6	(5,415,919)	(2,029,692)
Retirement benefit income	17	(5,099,812)	-
Donated laboratory equipment	8	(2,757,694)	(2,480,093)
Loss from write-off of receivables	5	540,959	-
Interest income	4	(24,155)	(25,307)
Excess of revenues over expenses (expenses over revenues) before working capital changes		7,171,140	(5,597,216)
Decrease (increase) in:			
Receivables		2,325,608	(9,573,175)
Other current assets		231,058	(219,009)
Deferred input valued-added tax		(277,500)	(128,699)
Increase (decrease) in accrued expenses and other payables		(2,046,025)	3,904,139
Net cash generated from (used for) operations		7,404,281	(11,613,960)
Benefits paid	17	(316,773)	-
Income tax paid		(248,237)	(109,531)
Interest received		24,155	25,307
Net cash provided by (used in) operating activities		6,863,426	(11,698,184)
CASH FLOWS FROM INVESTING ACTIVITIES			
Proceeds from withdrawals of investments in trust funds		62,849,206	36,734,213
Additions to:			
Investments in trust funds		(57,390,651)	(17,779,436)
Property and equipment	8	(5,068,690)	(1,433,923)
Investment income received		5,415,919	2,029,692
Net cash provided by investing activities		5,805,784	19,550,546
NET INCREASE IN CASH AND CASH EQUIVALENTS		12,669,210	7,852,362
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR		18,842,676	10,990,314
CASH AND CASH EQUIVALENTS AT END OF YEAR	4	P31,511,886	P18,842,676
NONCASH FINANCIAL INFORMATION			
Donated laboratory equipment	8	P2,757,694	P2,480,093

See accompanying Notes to Financial Statements.

INDEPENDENT AUDITORS' REPORT

We have audited the accompanying financial statements of Tropical Disease Foundation, Inc. (the Foundation), a non-stock, non-profit organization, which comprise the statements of assets, liabilities and fund balances as at July 31, 2021 and 2020, and the statements of revenues and expenses, statements of changes in fund balances and statements of cash flows for the years then ended, including a summary of significant accounting policies.

In our opinion, the financial statements present fairly, in all material respects, the financial position of the Foundation as at July 31, 2021 and 2020, and its financial performance and its cash flows for the years then ended in accordance with Philippine Financial Reporting Standard for Small and Medium-sized Entities (PFRS for SME).

Basis for Opinion

We conducted our audits in accordance with Philippine Standards on Auditing (PSA). Our responsibilities under those standards are further described in the *Auditors' Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Foundation in accordance with the Code of Ethics for Professional Accountants in the Philippines (Code of Ethics) together with the ethical requirements that are relevant to the audit of the financial statements in the Philippines, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with PFRS for SME, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Foundation's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Foundation or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Foundation's financial reporting process.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with PSA will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, these could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with PSA, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the Foundation's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Foundation's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Foundation to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audits.

REYES TACANDONG & Co.


DAPHNE A. JAMOTILLO
Partner

CPA Certificate No. 100039
Tax Identification No. 206-551-995-000
BOA Accreditation No. 4782; Valid until April 13, 2024
SEC Accreditation No. 100039-SEC Group A
Issued August 3, 2021
Valid for Financial Periods 2021 to 2025
BIR Accreditation No. 08-005144-018-2021
Valid until July 1, 2024
PTR No. 8534290
Issued January 5, 2021, Makati City

November 8, 2021
Makati City, Metro Manila

BOARD OF TRUSTEES

CHAIRMAN OF THE BOARD

Ruben L. Encarnacion, PhD

MEMBERS

Arch. Pablo R. Antonio Jr.

Claver P. Ramos, MD

Manuel L. Lazaro, Esq.

Mrs. Mercedes Solon

Atty. Edwin Abella

Camilo C. Roa Jr., MD

Salvacion R. Gatchalian, MD

Socorro P. Lupisan, MD

MANAGEMENT STAFF

President

Roberta C. Romero, MD

VP for Program Support

Leilani C. Naval

Clinic Physician

Rholine Gem Martin S. Veto, MD

Head Nurse

Ma. Begonia R. Baliwagan, RN

Laboratory Manager

Anthony A. Geronimo, RMT

Finance Manager

Jovita P. Belen

General Services Department Manager

Marilou O. Guisic

Human Resource Department Manager

Marita I. Nucum

Information Technology Department Manager

Evelyn S. Joson

CONTACT US

Website: www.tdf.org.ph

Email: inquiries@tdf.org.ph

Telephone: +632 8894 0741/43